Jing Xu

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · New England Journal of Medicine · 2013 · 2.9K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn, Brian G. Feagan, Paul Rutgeerts et al. · New England Journal of Medicine · 2013 · 2.7K citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +14

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

Bruce E. Sands, Brian G. Feagan, Paul Rutgeerts et al. · Gastroenterology · 2014 · 705 citations · Full text

Medicine, Immunology, Pharmacology +15

Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

Bruce E. Sands, William J. Sandborn, Gert Van Assche et al. · Inflammatory Bowel Diseases · 2016 · 184 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Edible exosome-like nanoparticles from portulaca oleracea L mitigate DSS-induced colitis via facilitating double-positive CD4+CD8+T cells expansion

Min‐zheng Zhu, Haoming Xu, Jing Xu et al. · Journal of Nanobiotechnology · 2023 · 163 citations · Full text

Life Sciences, Immunology, Pathobiology +17